ClinicalTrials.gg
CompletedNCT07556549Updated Oct 30, 2026

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

An observational study in Non-Small Cell Lung Cancer ALK-positive, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Pfizer · Observational

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
13th of 17
50 · median 97
Started
2026
with 6 others
Observational
17 of 158
1 open now
Registered
155th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 13th largest by enrollment of the 17 observational ones that give a count, is one of 7 that started in 2026, is one of 17 observational ones, and was the 155th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC.

The participants included in this study are:

  • Aged 18 years or more
  • diagnosed with a/mNSCLC
  • confirmed with testing for ALK-positive
  • have started first-line lorlatinib treatment during the patient selection period

In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.

03

Conditions studied

  • Non-Small Cell Lung Cancer ALK-positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC, and initiated lorlatinib as first line treatment

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  1. Age ≥18 years
  2. Diagnosed with a/mNSCLC
  3. Confirmed testing for ALK-positive
  4. Initiated lorlatinib treatment during the patient selection period, prior therapy such as or neoadjuvant treatment are allowed.
  5. A minimum lookback period of at least 3 months to establish a baseline period and ensure first-line use of cohort entry drug
  6. Have at least 6 months of follow-up data available (early death or progression will be included)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (actual)
Patient registry
No

Groups and cohorts

  • Lorlatinib in locally advanced/metastatic ALK-positive Non-Small Cell Lung Cancer Patients in China

    Drug: Lorlatinib

Interventions

  • for the treatment of patients with locally advanced or metastatic ALK positive non-small cell lung cancer.

06

What researchers measure

Primary outcomes

  1. Age at Start of Lorlatinib Treatment

    Number of percentages of patients by age

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  2. Smoking status (if available) at Start of Lorlatinib Treatment

    Number of patients by smoking status

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  3. Histology of patients at start of Lorlatinib treatment

    Histology of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  4. Eastern Cooperative Oncology Group (ECOG) performance status of patients at Start of Lorlatinib Treatment

    number of Eastern Cooperative Oncology Group (ECOG) performance status of patients

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  5. Initial cancer stage at diagnosis of patients prior Start of Lorlatinib Treatment

    initial cancer stage of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  6. Current cancer stage at Start of Lorlatinib Treatment

    Current cancer stage of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  7. Brain metastases status at Start of Lorlatinib Treatment

    Brain metastases status of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  8. Date of initial NSCLC diagnosis

    Date of initial NSCLC diagnosis

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  9. Date of a/mNSCLC diagnosis

    Date of a/mNSCLC diagnosis of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  10. ALK-positive diagnosis prior to Start of Lorlatinib Treatment

    Date of patients with ALK-positive diagnosis

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  11. Gene testing method and results prior to initiation of lorlatinib treatment

    Gene testing method and results of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  12. Date of brain metastases diagnosis prior to initiation of lorlatinib treatment

    number and date of brain metastases diagnosis of patients for whom had BM prior lorlatinib treatment

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  13. Presence of comorbidities at Start of Lorlatinib Treatment

    Presence of comorbidities of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  14. Concomitant therapies at Start of Lorlatinib Treatment

    Concomitant therapies of patients were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  15. Date of lorlatinib initiation

    Date of Lorlatinib first prescription were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  16. Initial lorlatinib dose at Start of Lorlatinib Treatment

    Initial lorlatinib dose for patients receiving Lorlatinb treatment were reported in this outcome measure

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  17. Dose adjustments when patients were prescribed with Lorlatinib Treatment

    Dose adjustments of Lorlatinib Treatment and Date were reported in this outcome measure

    Time frame: From the date of initiation of lorlatinib treatment to the date of treatment dose adjustments, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  18. Gender at Start of Lorlatinib Treatment

    Number of patients by gender

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  19. Weight at Start of Lorlatinib Treatment

    Number of patients by weight

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  20. Height at Start of Lorlatinib Treatment

    Number of patients by height

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

  21. Body mass index (BMI) at Start of Lorlatinib Treatment

    Number of patients by BMI

    Time frame: At initiation of lorlatinib treatment between July 2022- October 2024

Secondary outcomes

  1. Time to Discontinuation (TTD) in 1 L lorlatinib patients

    Time to Discontinuation (TTD) was the time from the date of initiation of Lorlatinib Treatment to date if the permanent cessation of lorlatinib due to any reasons, including progression, adverse events, patient decision, or physician recommendation. TTD will be analyzed using Kaplan-Meier survival analysis.

    Time frame: From the date of first lorlatinib dose until permanent discontinuation of treatment for any cause, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  2. Last dose for Patients who are still on the Lorlatinib first line treatment

    Last dose for Patients who are still on the therapy were reported in this outcome measure

    Time frame: the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  3. Treatment switching to other ALK TKls from Lorlatinib Treatment

    Treatment switching to other ALK TKls was switching from lorlatinib to another ALK-TKIs due to any reasons. The Name of treatment regimen, Date of treatment switch and Duration of each switched regimen were recorded in this outcome measure.

    Time frame: From the date of initiation of other ALK TKIs to the study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  4. 1L lorlatinib resistance mechanism (if applicable)

    Characterization of acquired resistance mechanisms to first-line lorlatinib, including on-target ALK alterations and off-target/bypass pathway activations, as identified at disease progression.

    Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  5. Treatment switching to subsequence treatment from 1L Lorlatinib Treatment

    Treatment switching to subsequence treatment was switching from lorlatinib to another systemic therapy due to treatment failure caused by progression, intolerance, or physician decision. It was recorded in this outcome measure.

    Time frame: From the date of initiation of subsequent other treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  6. Medical Costs during lorlatinib treatment period

    Medical Costs during lorlatinib treatment period for patients were reported in this outcome measure, inducing drug costs, hospitalization costs, outpatient cost, and ect.

    Time frame: From the date of first lorlatinib dose until permanent discontinuation of treatment for any cause, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  7. Brain metastases progression and date of patients receiving Lorlatinib treatment

    Brain metastases progression was radiological confirmation of new or worsening intracranial lesions.

    Time frame: From the date of initiation of lorlatinib treatment to the date of BM progression, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  8. Death (if applicable) of patients receiving Lorlatinib for the first-line treatment

    percentage of Deaths (and date if applicable) of patients

    Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

  9. The cumulative incidence rate of BM of patients receiving Lorlatinib for the first-line treatment

    Percentage of number of patients with BM

    Time frame: From the date of initiation of lorlatinib treatment to the date of any-cause treatment discontinuation or study end, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).

07

Study locations

1 site
  • Pfizer
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2026 to primary completion in Sep 2026, 4 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Sep 2026 and completion Aug 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 29, 2026
StartActual
May 18, 2026
Primary completionActual
Sep 24, 2026was Aug 2026
CompletionActual
Sep 24, 2026was Aug 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Aug 30, 2026→Sep 24, 2026 (actual)
Oct 30, 2026
Study completion
Aug 30, 2026→Sep 24, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Primary completion Aug 30, 2026→Sep 24, 2026 (now actual)
    Study completion Aug 30, 2026→Sep 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07556549
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
May 18, 2026
Primary completion
Sep 24, 2026
Completion
Sep 24, 2026
Last update
Oct 30, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion